A year ago this week, we held the first patient-focused drug development (PFDD) meeting for LGSOC with the FDA. Not only was this a first for LGSOC but a first for ovarian cancer overall. One of the FDA’s missions is to protect and promote public health by evaluating the safety and effectiveness of new drugs, biologics, and devices. The FDA does not develop drugs nor conduct clinical trials. The FDA does, however, play a constructive role in guiding, helping, or evaluating the pre-clinical, translational, and clinical development work of potential new medications. The PFDD meeting gave the LGSOC community an opportunity to share their views and stories with the FDA, including the importance of developing and bringing more therapies to patients. STAAR partnered with Cure our Ovarian Cancer and World Ovarian Cancer Coalition on this meeting and the outcome of the meeting was a clear roadmap for what needs to improve. The information obtained at the meeting and summarized in this report is anticipated to lead to more dialogue between stakeholders in the LGSOC community, with the goal of gaining patients’ perspectives on their condition and therapies available to treat the condition to aid in decision-making for drug development and clinical trials for LGSOC, to ultimately improve the overall quality of life for patients. At a high level, what the meeting found are the following areas of need:
Thank you to everyone who shared their stories and participated in the meeting. A year after the meeting, STAAR continues to make significant strides in addressing the awareness, research and support needs in LGSOC. AuthorLisa Buffington is a patient advocacy consultant and volunteer with STAAR Ovarian Cancer Foundation.
0 Comments
|
Archives
February 2025
Categories |